I serve as the clinic director for the Lank Center for Genitourinary Oncology at Dana Farber Cancer Institute. My practice encompasses medical oncologic care for all genitourinary malignancies to include kidney, bladder, prostate, testicular and rare tumors.
From a research perspective, I am an active participant in clinical trials. In collaboration with others, we are exploring the role of combination immunotherapy in rare genitourinary cancers (non-traditional bladder and prostate cancer, adrenocortical cancer, treatment refractory testicular cancer, penile cancer) In addition, I am leading trials exploring novel combinations of immunotherapies with other agents in a variety of tumor types while also exploring the role of anti-body drug conjugates in heavily treated cases of kidney and bladder cancer.
I also am involved in efforts to better elucidate prognostic and predictive markers exploring different mutations on the tumor as well as blood based markers that may assist in future treatment decisions.